parthenolide has been researched along with Encapsulating Peritoneal Sclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, C; Feng, W; Huang, Y; Li, S; Liang, J; Lin, M; Long, H; Peng, X; Shen, H; Wang, Z; Xiao, L; Zhang, Y; Zhao, Y; Zhu, L | 1 |
| Chen, Y; Gong, W; Huang, Q; Li, S; Long, H; Luo, C; Peng, F; Peng, X; Wang, Y; Wu, J; Xiao, J; Yin, B; Zhang, Y; Zhou, W | 1 |
2 other study(ies) available for parthenolide and Encapsulating Peritoneal Sclerosis
| Article | Year |
|---|---|
Parthenolide alleviates peritoneal fibrosis by inhibiting inflammation via the NF-κB/ TGF-β/Smad signaling axis.
Topics: Animals; Dialysis Solutions; Epithelial-Mesenchymal Transition; Fibrosis; Glucose; Inflammation; Mice; NF-kappa B; Peritoneal Fibrosis; Peritoneum; Rats; Transforming Growth Factor beta1 | 2022 |
Parthenolide, an NF-κB inhibitor, alleviates peritoneal fibrosis by suppressing the TGF-β/Smad pathway.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Dialysis Solutions; Disease Models, Animal; Drug Evaluation, Preclinical; Epithelial-Mesenchymal Transition; Female; Humans; Male; Mice; Peritoneal Dialysis; Peritoneal Fibrosis; Peritoneum; Phosphorylation; Sesquiterpenes; Signal Transduction; Smad Proteins; Transforming Growth Factor beta1 | 2020 |